NR 566 Final Exam — Advanced Pharmacology for Care of the Family Chamberlain University 2026/2027 — 2 Latest Versions
NR 566 Final Exam
Advanced Pharmacology for Care of the Family
2 Latest Versions — 160 Questions Each (320 Total) | Questions & Verified Answers | 2026/2027 Newly
Updated
Aligned with Chamberlain University NR566 Curriculum, ANCC/AANP NP Competencies, and Evidence-Based
Prescribing Standards
Examination Overview: This comprehensive final exam package contains two complete 160-question versions covering
the full NR566 Advanced Pharmacology curriculum. Content spans advanced pharmacokinetics and pharmacodynamics
(CYP450 system, drug interactions, therapeutic drug monitoring, pharmacogenomics); legal, ethical, and prescriptive
authority (DEA regulations, controlled substances, scope of practice); cardiovascular pharmacology (antihypertensives,
anticoagulants, antidysrhythmics, heart failure, lipid management); antimicrobial stewardship (antibiotics, antivirals,
antifungals, resistance patterns); endocrine and diabetes pharmacology (insulins, oral antidiabetics, GLP-1 agonists,
SGLT2 inhibitors, thyroid agents); respiratory and asthma/COPD therapeutics (GINA guidelines, MART therapy);
neuropharmacology and mental health (antidepressants, antipsychotics, anxiolytics, mood stabilizers, ADHD medications);
pain management and controlled substances (opioids, NSAIDs, adjuvant analgesics, addiction treatment); special
populations (geriatric, pediatric, pregnancy/lactation, hepatic/renal impairment, pharmacogenomics); and comprehensive
case studies with integrated clinical decision-making. Each question includes the correct answer marked [CORRECT] and
a detailed rationale with evidence-based reasoning. Cognitive distribution: approximately 25% recall, 55% application,
20% analysis. Question style: 70% scenario-based, 25% direct recall, 5% calculation. Key high-yield topics include:
warfarin INR targets (2.0-3.0 AF; 2.5-3.5 mechanical valves), ACEi/ARB pregnancy contraindication
(methyldopa/labetalol/nifedipine preferred), amiodarone toxicity monitoring (PFTs, TSH), MAOI tyramine restrictions,
carbamazepine-CYP450 induction reducing OC effectiveness, statin CK monitoring, GINA MART therapy, TMP-SMX
for MRSA SSTI, digoxin hypokalemia risk, levothyroxine administration timing, and Beers Criteria for geriatric
prescribing.
VERSION 1 — Comprehensive 160-Question Final Exam
Section 1: Advanced Pharmacokinetics and Pharmacodynamics
Q1: A 68-year-old patient takes warfarin 5 mg daily for atrial fibrillation. The provider starts fluconazole for
oral candidiasis. Three days later, the patient's INR is 6.2. Which pharmacokinetic mechanism best explains
this interaction?
A. Fluconazole induces CYP2C9, increasing warfarin metabolism.
B. Fluconazole inhibits CYP2C9, reducing warfarin metabolism and increasing INR. [CORRECT]
C. Fluconazole increases warfarin protein binding.
D. Fluconazole enhances renal clearance of warfarin.
Correct Answer: B
Rationale: Warfarin is metabolized primarily by CYP2C9. Fluconazole is a potent CYP2C9 inhibitor; reduced warfarin
clearance leads to elevated plasma levels and a supratherapeutic INR, increasing bleeding risk. The provider should hold
warfarin, consider vitamin K, and choose an alternative antifungal. CYP inducers (e.g., rifampin) would decrease INR. CYP450
inducers/inhibitors are heavily tested on NR566.
Advanced Pharmacology Certification Prep — For Educational Use Page 1
,NR 566 Final Exam — Advanced Pharmacology for Care of the Family Chamberlain University 2026/2027 — 2 Latest Versions
Q2: A patient asks why a medication was prescribed sublingually rather than orally. Which pharmacokinetic
concept best explains the rationale for sublingual nitroglycerin administration?
A. Sublingual administration bypasses hepatic first-pass metabolism, producing rapid onset and higher bioavailability.
[CORRECT]
B. Sublingual administration increases first-pass metabolism.
C. Sublingual absorption is slower than oral.
D. Sublingual nitroglycerin has 100% renal excretion.
Correct Answer: A
Rationale: Sublingual administration allows drug absorption directly into the systemic circulation via the venous drainage of the
oral mucosa, bypassing the portal circulation and hepatic first-pass metabolism. This produces rapid onset (1-3 minutes for
nitroglycerin) and higher bioavailability. First-pass effect is a major determinant of oral bioavailability and is heavily tested in
NR566.
Q3: Which of the following is a CYP450 enzyme inducer that would be expected to DECREASE the
effectiveness of combined oral contraceptives?
A. Ketoconazole.
B. Grapefruit juice.
C. Carbamazepine. [CORRECT]
D. Cimetidine.
Correct Answer: C
Rationale: Carbamazepine is a potent CYP3A4 inducer that increases the metabolism of estrogen and progestin components of
combined oral contraceptives, reducing their effectiveness and increasing the risk of unintended pregnancy. Other inducers
include rifampin, phenytoin, and St. John's Wort. Ketoconazole, grapefruit juice, and cimetidine are CYP inhibitors that would
increase (not decrease) contraceptive levels. This interaction is a high-yield NR566 concept.
Q4: A patient has a creatinine clearance of 25 mL/min. Which pharmacokinetic parameter is most directly
affected and requires dose adjustment for renally cleared medications?
A. Absorption.
B. Distribution.
C. Metabolism.
D. Excretion (renal clearance reduced, prolonging half-life and increasing drug accumulation). [CORRECT]
Correct Answer: D
Rationale: Creatinine clearance reflects glomerular filtration rate and directly impacts renal excretion of drugs. With CrCl <30
mL/min, renally cleared drugs (e.g., gabapentin, metformin, vancomycin, aminoglycosides) accumulate, prolonging half-life and
increasing toxicity risk. Dose reduction or extended dosing intervals are required. Hepatic metabolism is less directly affected by
renal function. Renal dose adjustment is a foundational NR566 competency.
Q5: Which statement best distinguishes first-order from zero-order kinetics?
A. First-order kinetics: a constant amount of drug is eliminated per unit time; zero-order: a constant fraction.
B. First-order kinetics: a constant fraction of drug is eliminated per unit time (proportional to plasma concentration);
zero-order: a constant amount is eliminated per unit time (saturable metabolism). [CORRECT]
C. Both are identical.
D. First-order applies only to IV drugs.
Correct Answer: B
Rationale: First-order kinetics: a constant FRACTION of drug is eliminated per unit time (exponential decay), with half-life
remaining constant — most drugs follow this. Zero-order kinetics: a constant AMOUNT is eliminated per unit time due to
saturation of metabolic pathways (e.g., ethanol, high-dose phenytoin, aspirin at high doses), where half-life increases with dose.
Advanced Pharmacology Certification Prep — For Educational Use Page 2
,NR 566 Final Exam — Advanced Pharmacology for Care of the Family Chamberlain University 2026/2027 — 2 Latest Versions
Recognizing zero-order drugs is critical to avoid toxicity, as small dose increases can produce disproportionate plasma level
rises.
Q6: A patient on phenytoin has a subtherapeutic level. The provider doubles the dose from 300 mg to 600 mg
daily. The new level is supratherapeutic and the patient develops nystagmus and ataxia. Which
pharmacokinetic property explains this response?
A. Phenytoin follows first-order kinetics, so doubling the dose doubles the level.
B. Phenytoin follows zero-order (saturable) kinetics at therapeutic doses; small dose increases produce disproportionate
plasma level elevations. [CORRECT]
C. Phenytoin has a wide therapeutic index.
D. Phenytoin is renally cleared.
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (saturable, zero-order) kinetics within the therapeutic range. As dose increases,
the metabolic pathway saturates, and small dose increments produce large, non-linear plasma level increases. This is why
phenytoin requires level-targeted titration rather than empirical dose doubling. Nystagmus, ataxia, and cognitive changes are
classic signs of phenytoin toxicity. Therapeutic drug monitoring is essential.
Q7: Which of the following correctly describes the mechanism of a partial agonist?
A. Binds receptor and produces maximal response.
B. Binds receptor but produces submaximal response even at full receptor occupancy; can act as antagonist in presence
of full agonist. [CORRECT]
C. Blocks receptor without intrinsic activity.
D. Produces inverse response at receptor.
Correct Answer: B
Rationale: A partial agonist binds the receptor with affinity but produces submaximal efficacy (lower intrinsic activity) even at
full receptor occupancy. In the presence of a full agonist, a partial agonist acts as a competitive antagonist (e.g., buprenorphine
at mu receptors, aripiprazole at D2 receptors). Understanding partial agonism informs rational selection of opioid use disorder
therapies and antipsychotics with reduced metabolic/EPS burden.
Q8: A patient asks why therapeutic drug monitoring is required for digoxin. Which pharmacologic property
best supports the need for TDM?
A. Wide therapeutic index.
B. Narrow therapeutic index with significant toxicity risk, requiring plasma level monitoring to maintain levels within
0.5-2.0 ng/mL. [CORRECT]
C. Renal excretion only.
D. Zero-order kinetics.
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index (0.5-2.0 ng/mL), meaning the toxic dose is close to the therapeutic dose.
TDM ensures efficacy while avoiding toxicity (arrhythmias, GI, visual disturbances). Hypokalemia, hypomagnesemia, and renal
impairment increase toxicity risk. Other narrow-therapeutic-index drugs requiring TDM include lithium, aminoglycosides,
vancomycin, phenytoin, and warfarin. TDM is a core NR566 concept.
Q9: A patient asks about the volume of distribution (Vd) of a drug. Which statement is correct?
A. Vd is the actual physiologic volume of plasma.
B. Vd is an apparent volume that relates drug dose to plasma concentration; high Vd indicates extensive tissue
distribution (e.g., lipophilic drugs like amiodarone), while low Vd suggests restriction to plasma. [CORRECT]
C. Vd determines oral bioavailability.
Advanced Pharmacology Certification Prep — For Educational Use Page 3
, NR 566 Final Exam — Advanced Pharmacology for Care of the Family Chamberlain University 2026/2027 — 2 Latest Versions
D. Vd is the same for all patients.
Correct Answer: B
Rationale: Volume of distribution (Vd) is an apparent (theoretical) volume relating administered dose to resulting plasma
concentration. High Vd (e.g., amiodarone 60 L/kg, digoxin 7 L/kg) indicates extensive tissue distribution, often due to
lipophilicity or tissue binding. Low Vd (e.g., warfarin 0.14 L/kg) indicates restriction to plasma, often due to high protein
binding. Vd influences loading dose calculations and dialyzability — high Vd drugs are poorly dialyzable.
Q10: Which drug interaction mechanism is responsible for the interaction between warfarin and TMP-SMX
(Bactrim)?
A. TMP-SMX induces warfarin metabolism.
B. TMP-SMX inhibits warfarin metabolism (CYP2C9 inhibition) and displaces warfarin from protein binding,
increasing INR. [CORRECT]
C. TMP-SMX increases warfarin renal excretion.
D. TMP-SMX decreases warfarin absorption.
Correct Answer: B
Rationale: TMP-SMX interacts with warfarin through two mechanisms: (1) CYP2C9 inhibition reduces warfarin metabolism; (2)
displacement from albumin protein binding transiently increases free warfarin. Both effects increase INR and bleeding risk.
Patients on warfarin requiring TMP-SMX should have INR monitored closely, with warfarin dose reduction often needed. This is
a high-yield drug interaction tested on NR566.
Q11: Grapefruit juice inhibits which CYP450 enzyme, leading to increased levels of many medications
including some statins and calcium channel blockers?
A. CYP2D6.
B. CYP3A4 (intestinal), increasing bioavailability of CYP3A4 substrates. [CORRECT]
C. CYP2C9.
D. CYP1A2.
Correct Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4, increasing bioavailability of orally administered CYP3A4
substrates such as simvastatin, lovastatin, atorvastatin, felodipine, and cyclosporine. The effect can last 24-72 hours. Patients
should be counseled to avoid grapefruit juice when taking affected medications to prevent toxicity (e.g., statin-induced myopathy,
hypotension). Other CYP3A4 inhibitors include ketoconazole, clarithromycin, and ritonavir.
Q12: A patient on long-term lithium therapy presents with tremor, ataxia, and confusion. Lithium level is 2.0
mEq/L. Which pharmacokinetic factor most commonly contributes to lithium toxicity?
A. Hepatic enzyme inhibition.
B. Reduced renal clearance due to dehydration, NSAIDs, ACE inhibitors, or thiazide diuretics that increase lithium
reabsorption. [CORRECT]
C. Increased protein binding.
D. Enhanced GI absorption.
Correct Answer: B
Rationale: Lithium is excreted renally with a narrow therapeutic index (0.6-1.2 mEq/L). Reduced renal clearance — from
dehydration, NSAIDs (decrease renal perfusion), thiazides (increase proximal lithium reabsorption), or ACE inhibitors —
precipitates toxicity. Symptoms progress from mild (tremor, GI) to severe (seizures, renal failure) at levels >2.5 mEq/L.
PMHNPs/NPs must counsel patients to maintain hydration and report symptoms promptly.
Q13: A patient with a CYP2D6 poor metabolizer phenotype is prescribed codeine for post-operative pain.
Which outcome is most likely?
Advanced Pharmacology Certification Prep — For Educational Use Page 4
NR 566 Final Exam
Advanced Pharmacology for Care of the Family
2 Latest Versions — 160 Questions Each (320 Total) | Questions & Verified Answers | 2026/2027 Newly
Updated
Aligned with Chamberlain University NR566 Curriculum, ANCC/AANP NP Competencies, and Evidence-Based
Prescribing Standards
Examination Overview: This comprehensive final exam package contains two complete 160-question versions covering
the full NR566 Advanced Pharmacology curriculum. Content spans advanced pharmacokinetics and pharmacodynamics
(CYP450 system, drug interactions, therapeutic drug monitoring, pharmacogenomics); legal, ethical, and prescriptive
authority (DEA regulations, controlled substances, scope of practice); cardiovascular pharmacology (antihypertensives,
anticoagulants, antidysrhythmics, heart failure, lipid management); antimicrobial stewardship (antibiotics, antivirals,
antifungals, resistance patterns); endocrine and diabetes pharmacology (insulins, oral antidiabetics, GLP-1 agonists,
SGLT2 inhibitors, thyroid agents); respiratory and asthma/COPD therapeutics (GINA guidelines, MART therapy);
neuropharmacology and mental health (antidepressants, antipsychotics, anxiolytics, mood stabilizers, ADHD medications);
pain management and controlled substances (opioids, NSAIDs, adjuvant analgesics, addiction treatment); special
populations (geriatric, pediatric, pregnancy/lactation, hepatic/renal impairment, pharmacogenomics); and comprehensive
case studies with integrated clinical decision-making. Each question includes the correct answer marked [CORRECT] and
a detailed rationale with evidence-based reasoning. Cognitive distribution: approximately 25% recall, 55% application,
20% analysis. Question style: 70% scenario-based, 25% direct recall, 5% calculation. Key high-yield topics include:
warfarin INR targets (2.0-3.0 AF; 2.5-3.5 mechanical valves), ACEi/ARB pregnancy contraindication
(methyldopa/labetalol/nifedipine preferred), amiodarone toxicity monitoring (PFTs, TSH), MAOI tyramine restrictions,
carbamazepine-CYP450 induction reducing OC effectiveness, statin CK monitoring, GINA MART therapy, TMP-SMX
for MRSA SSTI, digoxin hypokalemia risk, levothyroxine administration timing, and Beers Criteria for geriatric
prescribing.
VERSION 1 — Comprehensive 160-Question Final Exam
Section 1: Advanced Pharmacokinetics and Pharmacodynamics
Q1: A 68-year-old patient takes warfarin 5 mg daily for atrial fibrillation. The provider starts fluconazole for
oral candidiasis. Three days later, the patient's INR is 6.2. Which pharmacokinetic mechanism best explains
this interaction?
A. Fluconazole induces CYP2C9, increasing warfarin metabolism.
B. Fluconazole inhibits CYP2C9, reducing warfarin metabolism and increasing INR. [CORRECT]
C. Fluconazole increases warfarin protein binding.
D. Fluconazole enhances renal clearance of warfarin.
Correct Answer: B
Rationale: Warfarin is metabolized primarily by CYP2C9. Fluconazole is a potent CYP2C9 inhibitor; reduced warfarin
clearance leads to elevated plasma levels and a supratherapeutic INR, increasing bleeding risk. The provider should hold
warfarin, consider vitamin K, and choose an alternative antifungal. CYP inducers (e.g., rifampin) would decrease INR. CYP450
inducers/inhibitors are heavily tested on NR566.
Advanced Pharmacology Certification Prep — For Educational Use Page 1
,NR 566 Final Exam — Advanced Pharmacology for Care of the Family Chamberlain University 2026/2027 — 2 Latest Versions
Q2: A patient asks why a medication was prescribed sublingually rather than orally. Which pharmacokinetic
concept best explains the rationale for sublingual nitroglycerin administration?
A. Sublingual administration bypasses hepatic first-pass metabolism, producing rapid onset and higher bioavailability.
[CORRECT]
B. Sublingual administration increases first-pass metabolism.
C. Sublingual absorption is slower than oral.
D. Sublingual nitroglycerin has 100% renal excretion.
Correct Answer: A
Rationale: Sublingual administration allows drug absorption directly into the systemic circulation via the venous drainage of the
oral mucosa, bypassing the portal circulation and hepatic first-pass metabolism. This produces rapid onset (1-3 minutes for
nitroglycerin) and higher bioavailability. First-pass effect is a major determinant of oral bioavailability and is heavily tested in
NR566.
Q3: Which of the following is a CYP450 enzyme inducer that would be expected to DECREASE the
effectiveness of combined oral contraceptives?
A. Ketoconazole.
B. Grapefruit juice.
C. Carbamazepine. [CORRECT]
D. Cimetidine.
Correct Answer: C
Rationale: Carbamazepine is a potent CYP3A4 inducer that increases the metabolism of estrogen and progestin components of
combined oral contraceptives, reducing their effectiveness and increasing the risk of unintended pregnancy. Other inducers
include rifampin, phenytoin, and St. John's Wort. Ketoconazole, grapefruit juice, and cimetidine are CYP inhibitors that would
increase (not decrease) contraceptive levels. This interaction is a high-yield NR566 concept.
Q4: A patient has a creatinine clearance of 25 mL/min. Which pharmacokinetic parameter is most directly
affected and requires dose adjustment for renally cleared medications?
A. Absorption.
B. Distribution.
C. Metabolism.
D. Excretion (renal clearance reduced, prolonging half-life and increasing drug accumulation). [CORRECT]
Correct Answer: D
Rationale: Creatinine clearance reflects glomerular filtration rate and directly impacts renal excretion of drugs. With CrCl <30
mL/min, renally cleared drugs (e.g., gabapentin, metformin, vancomycin, aminoglycosides) accumulate, prolonging half-life and
increasing toxicity risk. Dose reduction or extended dosing intervals are required. Hepatic metabolism is less directly affected by
renal function. Renal dose adjustment is a foundational NR566 competency.
Q5: Which statement best distinguishes first-order from zero-order kinetics?
A. First-order kinetics: a constant amount of drug is eliminated per unit time; zero-order: a constant fraction.
B. First-order kinetics: a constant fraction of drug is eliminated per unit time (proportional to plasma concentration);
zero-order: a constant amount is eliminated per unit time (saturable metabolism). [CORRECT]
C. Both are identical.
D. First-order applies only to IV drugs.
Correct Answer: B
Rationale: First-order kinetics: a constant FRACTION of drug is eliminated per unit time (exponential decay), with half-life
remaining constant — most drugs follow this. Zero-order kinetics: a constant AMOUNT is eliminated per unit time due to
saturation of metabolic pathways (e.g., ethanol, high-dose phenytoin, aspirin at high doses), where half-life increases with dose.
Advanced Pharmacology Certification Prep — For Educational Use Page 2
,NR 566 Final Exam — Advanced Pharmacology for Care of the Family Chamberlain University 2026/2027 — 2 Latest Versions
Recognizing zero-order drugs is critical to avoid toxicity, as small dose increases can produce disproportionate plasma level
rises.
Q6: A patient on phenytoin has a subtherapeutic level. The provider doubles the dose from 300 mg to 600 mg
daily. The new level is supratherapeutic and the patient develops nystagmus and ataxia. Which
pharmacokinetic property explains this response?
A. Phenytoin follows first-order kinetics, so doubling the dose doubles the level.
B. Phenytoin follows zero-order (saturable) kinetics at therapeutic doses; small dose increases produce disproportionate
plasma level elevations. [CORRECT]
C. Phenytoin has a wide therapeutic index.
D. Phenytoin is renally cleared.
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (saturable, zero-order) kinetics within the therapeutic range. As dose increases,
the metabolic pathway saturates, and small dose increments produce large, non-linear plasma level increases. This is why
phenytoin requires level-targeted titration rather than empirical dose doubling. Nystagmus, ataxia, and cognitive changes are
classic signs of phenytoin toxicity. Therapeutic drug monitoring is essential.
Q7: Which of the following correctly describes the mechanism of a partial agonist?
A. Binds receptor and produces maximal response.
B. Binds receptor but produces submaximal response even at full receptor occupancy; can act as antagonist in presence
of full agonist. [CORRECT]
C. Blocks receptor without intrinsic activity.
D. Produces inverse response at receptor.
Correct Answer: B
Rationale: A partial agonist binds the receptor with affinity but produces submaximal efficacy (lower intrinsic activity) even at
full receptor occupancy. In the presence of a full agonist, a partial agonist acts as a competitive antagonist (e.g., buprenorphine
at mu receptors, aripiprazole at D2 receptors). Understanding partial agonism informs rational selection of opioid use disorder
therapies and antipsychotics with reduced metabolic/EPS burden.
Q8: A patient asks why therapeutic drug monitoring is required for digoxin. Which pharmacologic property
best supports the need for TDM?
A. Wide therapeutic index.
B. Narrow therapeutic index with significant toxicity risk, requiring plasma level monitoring to maintain levels within
0.5-2.0 ng/mL. [CORRECT]
C. Renal excretion only.
D. Zero-order kinetics.
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index (0.5-2.0 ng/mL), meaning the toxic dose is close to the therapeutic dose.
TDM ensures efficacy while avoiding toxicity (arrhythmias, GI, visual disturbances). Hypokalemia, hypomagnesemia, and renal
impairment increase toxicity risk. Other narrow-therapeutic-index drugs requiring TDM include lithium, aminoglycosides,
vancomycin, phenytoin, and warfarin. TDM is a core NR566 concept.
Q9: A patient asks about the volume of distribution (Vd) of a drug. Which statement is correct?
A. Vd is the actual physiologic volume of plasma.
B. Vd is an apparent volume that relates drug dose to plasma concentration; high Vd indicates extensive tissue
distribution (e.g., lipophilic drugs like amiodarone), while low Vd suggests restriction to plasma. [CORRECT]
C. Vd determines oral bioavailability.
Advanced Pharmacology Certification Prep — For Educational Use Page 3
, NR 566 Final Exam — Advanced Pharmacology for Care of the Family Chamberlain University 2026/2027 — 2 Latest Versions
D. Vd is the same for all patients.
Correct Answer: B
Rationale: Volume of distribution (Vd) is an apparent (theoretical) volume relating administered dose to resulting plasma
concentration. High Vd (e.g., amiodarone 60 L/kg, digoxin 7 L/kg) indicates extensive tissue distribution, often due to
lipophilicity or tissue binding. Low Vd (e.g., warfarin 0.14 L/kg) indicates restriction to plasma, often due to high protein
binding. Vd influences loading dose calculations and dialyzability — high Vd drugs are poorly dialyzable.
Q10: Which drug interaction mechanism is responsible for the interaction between warfarin and TMP-SMX
(Bactrim)?
A. TMP-SMX induces warfarin metabolism.
B. TMP-SMX inhibits warfarin metabolism (CYP2C9 inhibition) and displaces warfarin from protein binding,
increasing INR. [CORRECT]
C. TMP-SMX increases warfarin renal excretion.
D. TMP-SMX decreases warfarin absorption.
Correct Answer: B
Rationale: TMP-SMX interacts with warfarin through two mechanisms: (1) CYP2C9 inhibition reduces warfarin metabolism; (2)
displacement from albumin protein binding transiently increases free warfarin. Both effects increase INR and bleeding risk.
Patients on warfarin requiring TMP-SMX should have INR monitored closely, with warfarin dose reduction often needed. This is
a high-yield drug interaction tested on NR566.
Q11: Grapefruit juice inhibits which CYP450 enzyme, leading to increased levels of many medications
including some statins and calcium channel blockers?
A. CYP2D6.
B. CYP3A4 (intestinal), increasing bioavailability of CYP3A4 substrates. [CORRECT]
C. CYP2C9.
D. CYP1A2.
Correct Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4, increasing bioavailability of orally administered CYP3A4
substrates such as simvastatin, lovastatin, atorvastatin, felodipine, and cyclosporine. The effect can last 24-72 hours. Patients
should be counseled to avoid grapefruit juice when taking affected medications to prevent toxicity (e.g., statin-induced myopathy,
hypotension). Other CYP3A4 inhibitors include ketoconazole, clarithromycin, and ritonavir.
Q12: A patient on long-term lithium therapy presents with tremor, ataxia, and confusion. Lithium level is 2.0
mEq/L. Which pharmacokinetic factor most commonly contributes to lithium toxicity?
A. Hepatic enzyme inhibition.
B. Reduced renal clearance due to dehydration, NSAIDs, ACE inhibitors, or thiazide diuretics that increase lithium
reabsorption. [CORRECT]
C. Increased protein binding.
D. Enhanced GI absorption.
Correct Answer: B
Rationale: Lithium is excreted renally with a narrow therapeutic index (0.6-1.2 mEq/L). Reduced renal clearance — from
dehydration, NSAIDs (decrease renal perfusion), thiazides (increase proximal lithium reabsorption), or ACE inhibitors —
precipitates toxicity. Symptoms progress from mild (tremor, GI) to severe (seizures, renal failure) at levels >2.5 mEq/L.
PMHNPs/NPs must counsel patients to maintain hydration and report symptoms promptly.
Q13: A patient with a CYP2D6 poor metabolizer phenotype is prescribed codeine for post-operative pain.
Which outcome is most likely?
Advanced Pharmacology Certification Prep — For Educational Use Page 4
